Concepedia

James M. Hamby

JM

Statistics

Publications

24

Citations

1.2K

H-Index

19

Active since

1987

Affiliations

University of Auckland(Current)

Cancer Society of New Zealand

Michigan Medicine

Pfizer (United States)

James M. Hamby is an author at University of Auckland specializing in medicinal chemistry, pharmacology, and enzyme inhibition.

Publications per year

1987–2011

24

Publications

24

Structure−Activity Relationships for a Novel Series of Pyrido[2,3-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors

James M. Hamby, Cleo J. C. Connolly, Mel C. Schroeder et al. · Journal of Medicinal Chemistry · 1997 · 142 citations · Full text

, , +17

2-Substituted Aminopyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity

S. KLUTCHKO, James M. Hamby, Diane H. Boschelli et al. · Journal of Medicinal Chemistry · 1998 · 130 citations · Full text

, , +17

In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor

Robert L. Panek, Gina H. Lu, S. KLUTCHKO et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 94 citations

, , +17

In Vitro Biological Characterization and Antiangiogenic Effects of PD 166866, a Selective Inhibitor of the FGF-1 Receptor Tyrosine Kinase

Robert L. Panek, Gina H. Lu, Tawny K. Dahring et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 89 citations · Full text

, , +17

Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-<i>d</i>]pyrimidine Inhibitors

Susanne Trumpp-Kallmeyer, John R. Rubin, Christine Humblet et al. · Journal of Medicinal Chemistry · 1998 · 85 citations · Full text

, , +17

1–5 of 24